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Abstract 
 
Neurotensin (NT) exerts naloxone-insensitive antinociceptive action through its binding to both 
NTS1 and NTS2 receptors and NT analogs provide stronger pain relief than morphine on a 
molecular basis. Here, we examined the analgesic/adverse effect profile of a new NT(8-13) 
derivative denoted JMV2009, in which the Pro10 residue was substituted by a silicon-containing 
unnatural amino acid silaproline. We first report the synthesis and in vitro characterization 
(receptor-binding affinity, functional activity and stability) of JMV2009. We next examined its 
analgesic activity in a battery of acute, tonic and chronic pain models. We finally evaluated its 
ability to induce adverse effects associated with chronic opioid use, such as constipation and 
analgesic tolerance or related to NTS1 activation, like hypothermia. In in vitro assays, JMV2009 
exhibited high binding affinity for both NTS1 and NTS2, improved proteolytic resistance as well 
as agonistic activities similar to NT, inducing sustained activation of p42/p44 MAPK and receptor 
internalization. Intrathecal injection of JMV2009 produced dose-dependent antinociceptive 
responses in the tail-flick test and almost completely abolished the nociceptive-related behaviors 
induced by chemical somatic and visceral noxious stimuli. Likewise, increasing doses of JMV2009 
significantly reduced tactile allodynia and weight bearing deficits in nerve-injured rats. 
Importantly, chronic agonist treatment did not result in the development of analgesic tolerance. 
Furthermore, JMV2009 did not cause constipation and was ineffective in inducing hypothermia. 
These findings suggest that NT drugs can act as an effective opioid-free medication for the 
management of pain or can serve as adjuvant analgesics to reduce the opioid adverse effects.   
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1. Introduction  
 
Today, opioids remain at the forefront of the pharmacological treatment of chronic pain (1, 
2). However, opioid therapy is associated with a wide range of side effects, such as constipation, 
nausea, drowsiness, dizziness, sleep disturbance, dry mouth, respiratory depression and tolerance 
that negatively affects patients’ well-being and even discourages them for continuing their 
medications (3-6). In the ongoing opioid crisis, involving drug misuse, abuse, overdose and death 
(7), there is therefore an urgent need for new, effective and safe non-opioid analgesics to improve 
the care of patients suffering from chronic pain. 
Among the alternative to opioids, neurotensin (NT) receptors recently emerged as attractive 
targets to develop new painkillers (8). Through its binding with two G protein-coupled receptors 
(GPCRs), referred to as NTS1 and NTS2, the tridecapeptide NT(1-13) was indeed found to induce 
a potent opioid-independent analgesia in a variety of pain paradigms following systemic or central 
administration (9-12). Accordingly, it was pharmacologically demonstrated that the 
antinociceptive responses induced by NT and its analogs, designed and synthesized based on the 
minimal biologically active C-terminal region (Arg8-Arg9-Pro10-Tyr11-Ile12-Leu13), could not be 
reversed by the opioid antagonists, naloxone and naltrexone (13-16). Importantly, NT was also 
reported to provide stronger pain relief than morphine on a molecular basis (17, 18).  
In the last two decades, peptide therapeutics have gained increased interest from the 
biomedical and pharmaceutical industry, filling the gap between the two main classes of available 
market drugs, small molecules and biologics (19, 20). Peptides are definitely attractive drug 
candidates due to their high potency/efficacy, target specificity and safety/tolerability profile. 
Despite offering many advantages, their extensive use as therapeutics is, however, limited by their 
short half-life and rapid plasma clearance, which leads to low bioavailability (19, 21). Several 
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strategies have therefore been developed to overcome the undesirable physicochemical properties 
of therapeutic peptides. These approaches successfully applied to the C-terminal NT(8-13) 
hexapeptide include backbone and side-chain modifications, such as D-amino acid and non-natural 
amino acid substitutions, incorporation of reduced bonds, lactam bridged mimetics or peptide-
peptoid hybrids, N- and C-terminal modifications as well as introduction of conformational 
constraints via cyclization (12, 15, 22-30). 
According to recent structure-activity relationship (SAR) studies, structural modifications 
with unnatural amino acids were effective in producing NT(8-13) analogs with improved metabolic 
stability, receptor selectivity and in vivo activity (23, 26, 27, 30-33). In that respect, non-natural 
silylated amino acids are of great interest for their ability to modulate the physicochemical 
properties of bioactive peptides (26, 34-38). Herein, we report the synthesis and in vitro/in vivo 
characterization of a new NT(8-13) analog, named JMV2009, which binds to both NTS1 and NTS2 
receptors. In this compound, the Pro10 residue was substituted by a silicon-containing unnatural 
amino acid proline surrogate, denoted silaproline (Sip), which has been shown to retain peptide 
conformation (35, 39-41). This Sip-containing NT(8-13) analog was further screened in a battery 
of pain models to assess its putative analgesic properties and evaluate for its ability to induce 
adverse effects associated with chronic opioid therapy, such as constipation or analgesic tolerance. 
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2. Materials and methods 
 
2.1. Materials 
All cell culture media and supplements were from Wisent (St-Bruno, QC, Canada). CHO-
K1 cells stably expressing NTS1, 1321N1 cells stably expressing NTS2, and [125I]-[Tyr3]-NT were 
purchased from PerkinElmer (Billerica, MA, USA). All chemicals were from Fisher Scientific 
(Ottawa, ON, Canada) unless otherwise stated. Whatman GF/C glass fiber filters were obtained 
through VWR (Ville Mont-Royal, QC, Canada). Neurotensin was synthesized by the peptide 
synthesis core facility of the Institut de Pharmacologie de Sherbrooke 
(https://www.usherbrooke.ca/ips/fr/plateformes/). PD149163 was obtained by the U.S. National 
Institute of Mental Health, Chemical Synthesis and Drug Supply Program. Morphine sulfate was 
purchased from Sandoz (Boucherville, QC, Canada). 
2.2. JMV2009 synthesis 
Synthesis of JMV2009 is detailed in the Supplementary materials and methods. A synthesis 
synopsis is presented in Supplementary Figure S1 and its chemical structure is presented in 
Supplementary Scheme S1. 
2.3. Cell culture 
Cell lines stably expressing either the human NTS1 receptor (CHO-K1 cells, Cat# ES-690-
C) or NTS2 receptor (1321N1 cells, Cat# ES-691-C) were cultured in DMEM/F-12 (CHO-K1) or 
in DMEM (1321N1). Culture media were supplemented with 10 % fetal bovine serum (FBS), 100 
U/ml penicillin-streptomycin, 2 mM L-glutamine, 20 mM HEPES, and 0.4 mg/mL of G418. Cells 
were kept in a humidified atmosphere with 5% CO2 at 37oC. All cell lines were used between 
passages 5 and 25. 
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2.4. Radioligand binding experiments 
Binding experiments were carried out on freshly prepared membrane homogenates as 
previously described (26). Briefly, competition radioligand binding experiments were performed 
by incubating cell membranes (50 µg) with 0.1 nM (for NTS1) or 0.4 nM (for NTS2) of 125I-[Tyr3]-
NT (2,200 Ci/mmol) and increasing concentrations of ligands (10-11 to 10-5 M) for 30 min at 25°C 
in 250 µL binding buffer (50 mM Tris HCl, pH 7.5, containing 0.2 % BSA). Binding reaction was 
stopped by adding 2 mL of ice-cold binding buffer followed by filtration through glass microfiber 
filters (GF/C, Whatman) pre-incubated overnight with 0.5% polyethylenimine in 50 mM Tris HCl, 
pH 7.5. After washing twice with 2 mL ice-cold binding buffer, radioactivity retained on the filter 
was counted on a γ-counter (1470 Wizard from PerkinElmer). Nonspecific binding was measured 
in the presence of 10-5 M unlabeled NT and represented less than 5 % of total binding. IC50 values 
were determined from inhibition curves as the unlabeled ligand concentration inhibiting 50 % of 
125I-[Tyr3]-NT specific binding. All binding data were calculated using Prism v7.0a (GraphPad, La 
Jolla, CA, USA) using the One site – Fit Log(IC50) and represent the mean ± SEM of three separate 
determinations.  
2.5. Plasma stability 
Rat plasma (27 µL; obtained from rat blood after centrifugation at 15000 g over 5 min at 
4°C) and 1 mM aqueous solution of ligand (6 µL) were incubated at 37°C for 5, 10, 15, and 20 
min. The reaction was stopped by adding 70 µL of CH3CN. After mixing and centrifugation at 
15,000 g for 20 min at 4°C, the supernatant was analyzed by HPLC/UV (λ=230 nm). To quantify 
ligand degradation, 1 mM solution of Fmoc-Gly (6 µL) was added in each sample as a reference 
standard just before HPLC analysis. The percentage of remaining compound (not degraded) was 
calculated by determining the ratio between the area under the curve (AUC) of Fmoc-Gly and AUC 
of the test compound. The remaining percentage of peptide was plotted using Prism v7.0a and 
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represents the mean ± SEM of three determinations each done in triplicate. Half-life of each 
compound was calculated by fitting a one-phase decay non-linear regression using Prism v7.0a. 
2.6. Animals 
Experimental procedures were approved by the Animal Care and Ethical Committee of the 
Université de Sherbrooke (experiments involving rats) and Université de Rouen (experiments 
involving mice) and were in accordance with policies and directives of the Canadian and French 
Council on Animal Care, respectively. Furthermore, all procedures involving animals followed the 
ARRIVE recommendations (42). 
Adult male Sprague-Dawley rats (200-225 g; Charles River Laboratories, St-Constant, 
Quebec, Canada) or adult male Swiss albino mice (CD1, 22-26 g, Charles River, St-Aubin-les-
Elbeuf, France) were both maintained on a 12:12 hrs light/dark cycle with access to food and water 
ad libitum. Animals were acclimated for four days to the animal facility and for two days to the 
manipulations and testing devices prior to behavioral studies. 
2.7. Behavioral studies 
2.7.1. Intracerebroventricular injections 
 The intracerebroventricular injections (i.c.v.) were performed in conscious mice according 
to the method of Haley and McCormick (43) in a volume of 10 µL/mouse. 
2.7.2. Intrathecal injections 
 Rats were lightly anesthetized with 2% isofluorane. Subsequently, a 25 µL volume of 
compound or vehicle was administered by injection into the subarachnoid space between lumbar 
vertebrae L5 and L6, using a 27 G 1/2 needle. 
2.7.3. Acute pain test (Tail-Flick test) 
Acute nociception was investigated using the tail-flick test. Thermal threshold latencies 
were determined at baseline and at 10, 20, 30, 40, 50, 60, and 90 minutes after intrathecal (i.t.) 
  10 
injection of JMV2009 or vehicle. Testing involved measuring the tail withdrawal latency (in 
seconds) after immersion in a 52˚C water bath. Six centimeters of the rat’s tail were submerged in 
water and the latency to flick or curl the tail was recorded. Baseline responses (before drug 
administration) were typically ranging from 3 to 4 seconds. A cut-off was imposed at 10 seconds 
to avoid tissue damage. The mean latency at peak effect (40 min) was used for the determination 
of the analgesic efficacy and was converted to % of maximal possible effect (MPE) according to 
the formula: % maximum possible effect = [(test latency) − (baseline latency)]/[(cut-off) − 
(baseline latency)] × 100. 
2.7.4. Formalin tonic pain test  
Persistent pain was assessed using the formalin test. For this purpose, rats were placed for 
a 60-min habituation period in the experimentation room two days before the test. On the test day, 
rats received 50 μl subcutaneous injection of diluted 2% formaldehyde into the plantar surface of 
the right hind paw five min. after i.t. injection of JMV2009 or saline. Rats were then immediately 
placed in clear plastic chambers (40 × 30 × 30 cm) positioned over a mirror angled at 45°, to allow 
an unobstructed view of the 4 paws. Behaviors were recorded for the next 60 min. An intra-plantar 
injection of formalin produces a biphasic nociceptive response that characterizes this tonic pain 
model (44). The two distinct phases of spontaneous pain behaviors that occur in rats are suggested 
to reflect a direct effect of formalin on sensory receptors (phase 1) and a longer lasting pain due to 
inflammation and central sensitization (phase 2). The nocifensive behaviors were assessed using a 
weighed score, as described previously by (45). A nociceptive mean score was determined for each 
3-min period by measuring the amount of time spent in each of four behavioral categories: 0, the 
injected paw is comparable to the contralateral paw; 1, the injected paw has little or no weight 
placed on it; 2, the injected paw is elevated and is not in contact with any surface; 3, the injected 
paw is licked, bitten, or shaken. The total AUC for the inflammatory phase (phase 2) was calculated 
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between 21 to 60 min for each animal (46). 
2.7.5. Visceral pain test 
The intraperitoneal (i.p.) injection of a chemical irritant in mice induces a visceral noxious 
response characterized by a wave of constriction followed by elongation of the abdominal wall 
(47). This tonic visceral nociceptive response is often described as the writhing test (48). Briefly, 
mice received an intracerebroventricular (i.c.v.) injection of saline or JMV2009 20 min before i.p. 
administration of an acetic acid solution (0.5%). The number of writhes produced for a 5-min 
period was then counted beginning 5 min after i.p. injection. 
2.7.6. Chronic Construction Injury (CCI) of the sciatic nerve  
The surgical procedure of the neuropathic pain model was performed as previously 
described by (49) with a modification in the suture used (5-0 Prolene, Ethicon, Inc. Somerville, NJ, 
USA) in order to minimize suture-induced inflammation. Briefly, animals were anesthetized using 
3% isoflurane and the left sciatic nerve was loosely ligatured with 4 sutures distant by 1 mm 
upstream of the tibial, sural, and common peroneal nerve trifurcation. The muscle, conjunctive 
tissue and skin were closed with proper sutures and washed with 3% (v/v) hydrogen peroxide. 
Sham animals received the surgery, but no ligation of the sciatic nerve was performed. Rats were 
housed for 24 h in separate cages to recover from the surgery and were not given any medication 
to control post-surgical pain. 
The pain-related behaviors were examined at day 0 (pre-surgery, considered the baseline 
[BL]) and at 3, 7, 14, 21, and 28 days after nerve injury. Animals were moved to the examination 
room at 8 a.m. and tested one hour later. Dynamic weight bearing (DWB) measurements were 
conducted immediately after the mechanical allodynia assessment.  
To determine the presence of mechanical allodynia, rats were placed in enclosures with an 
elevated wire mesh floor. A dynamic plantar aesthesiometer (Ugo Basile, Stoelting, IL, USA), 
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consisting of a metal probe (0.5 mm diameter), was directed against the hind paw pad exerting an 
upward force (3.33 g second-1). The force required to elicit a withdrawal response was measured 
in grams and automatically registered when the paw was withdrawn, or the pre-set cut-off was 
reached (50 g). Five values were taken alternately on ipsi- and contra-lateral hind paw at 15 s 
intervals. The percentage of anti-allodynia was calculated with the AUC of every treatment for the 
time period comprised between 3 and 28 days, with the use of the following equation: % anti-
allodynia =100 × [(CCI + drug) − CCI control]/(sham − CCI control). From the latter formula, 0% 
represents no anti-allodynic effect of the compound, while 100% corresponds to a complete relief 
of mechanical hypersensitivity. 
The DWB device (Bioseb, Boulogne, France) was used to evaluate the presence of non-
evoked pain. This apparatus was characterized previously by our group (50). Briefly, rats are 
allowed to move freely within a Plexiglas enclosure (22 × 22 × 30 cm) with a floor sensor composed 
of 44 × 44 captors (10.89 mm2 per captor). Pressure data and live recording are recorded and 
transmitted to a laptop computer. Raw pressure and visual data were colligated with the latest DWB 
software available at the time. To calculate weight recovery and rehabilitation, we used the same 
formula as the anti-allodynia, meaning that: % weight recovery (or rehabilitation) = 100 × 
[AUC(CCI + drug) – AUC(CCI control)]/[(AUC(sham) – AUC(CCI control)]. From this formula, 
0% represents no weight recovery (or rehabilitation) induced by the compound, while 100% 
corresponds to complete weight recovery or total rehabilitation. 
2.7.7. Gastro-intestinal motility assessment 
Constipation has been assessed by measuring the gastro-intestinal (GI) tract motility using 
the charcoal meal test. Food deprived (16 h) animals were injected s.c. with saline or the 
compounds to be tested. 30 min. after drug injection, 2-ml of a charcoal meal solution (5% arabic 
gum, 10% charcoal in water) was administered to the rats by gavage. Rats were euthanized exactly 
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60 min after, and the progression of the charcoal in the intestine was measured as a ratio of 
progression of the meal over the total length of the intestine. The results are presented as a 
percentage of progression of the charcoal meal in the intestine. 
2.7.8. Tolerance to the acute thermal pain test 
For tolerance experiments, rats were injected i.t. with 30 µg kg-1 day-1 of JMV2009 or with saline 
for five consecutive days. On the sixth day, tail-flick latencies were measured immediately before 
and over 90 min following i.t. injection of JMV2009 (90 µg kg-1). The analgesic effect of this sub-
chronic treatment was assessed using the tail-flick thermal sensitivity assay as described above. 
2.7.9. Core body temperature 
Body temperature was measured using a thermistor probe inserted into the rectum of adult 
Sprague-Dawley rats. Prior to testing, animals were individually acclimatized to manipulations and 
thermistor probe 5 min/day for three consecutive days. On the test day, temperature was measured 
before (baseline) and each 30 min for up to 90 min following i.t. injection of saline, JMV2009 (3, 
30 and 90 µg kg-1) or the NTS1-selective reference compound PD149163 (51). Variations in body 
temperature (Δ body temp) were determined as changes from baseline for each individual animal. 
2.8. Data analysis and statistical procedures 
Data were plotted as mean ± standard error (SEM) for all curves and bar graphs. Two-way 
ANOVAs followed by a Dunnett's post hoc test were performed for all curves. Kruskal-Wallis 
followed by a Dunn’s correction for multiple comparisons tests were performed for all bar graphs 
except for the weight recovery and rehabilitation where a Mann-Whitney rank comparison test was 
used. Prism v7.0a software was used for all statistical analyses. A P value < 0.05 was considered 
significant and significant differences between groups were represented by * P < 0.05, ** P < 0.01, 
and *** P < 0.001.  
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3. Results 
 
3.1. JMV2009 acts as a non-selective NT receptor agonist 
We report here the synthesis and pharmacological evaluation of a NT(8-13) analog 
(JMV2009) carrying an unnatural silicon-containing proline surrogate, the 4-(dimethyl)silaproline 
(Sip) in replacement of the proline residue at position 10 (Supplemental Figure S1 and 
Supplemental Scheme S1) . We first found that this silaproline-containing peptide exhibited 
relatively high and similar binding affinities for both NTS1 and NTS2 receptors, with only slightly 
reduced affinity compared to the native NT peptide (Table 1). Our results further demonstrated 
that the presence of this silylated proline residue at position 10 can increase peptide resistance to 
proteolytic degradation. Accordingly, around 80% of JMV2009 remained intact after 5-min 
incubation with rat plasma, compared to 15% for the native NT peptide, thus resulting in an 
improved peptide stability to proteases (Supplemental Figure S2). 
We next examined if this NT peptide derivative was still able to induce receptor activation, 
by studying its ability to stimulate known intracellular signaling pathways activated by the NT 
receptor family. We thus evaluated the phosphorylation level of the mitogen-activated protein 
kinase ERK1/2 after NT or JMV2009 stimulation using cell lines stably expressing either NTS1 or 
NTS2 receptors. Our results revealed that JMV2009 was able to induce ERK1/2 activation in a 
similar manner as NT in both NTS1- and NTS2-expressing cells (Supplemental Figure S3A-D 
and Supplemental Western Blots). We then assessed the ability of JMV2009 to trigger NTS1 
receptor internalization by cell surface enzyme-linked immunosorbent assay (ELISA). We 
observed that both NT and JMV2009 promoted NTS1 receptor internalization, resulting 
respectively in 59.35 ± 1.5% and 49.14 ± 1.3% reduction in receptor cell surface expression within 
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1 hour (Supplemental Figure S3E). Altogether, these results demonstrate that the substitution of 
Pro10 by Sip leads to a functional NT agonist that may provide pain relief. 
 
3.2. Central delivery of JMV2009 significantly reduces acute and tonic pain 
We first used the tail-flick acute pain model to evaluate whether intrathecal (i.t.) delivery 
of JMV2009 attenuated the withdrawal responses to thermal nociceptive stimuli. We found that i.t. 
delivery of JMV2009 in rats elicited a dose-dependent antinociceptive response up to 60 min after 
injection, characterized by an increased tail-flick latency compared to saline-treated animals 
(Figure 1A). Peak analgesic responses occurred 40 min after JMV2009 injection, tail-flick 
latencies returning to baseline by 90 min. Comparison of % MPE at 40 min following JMV2009 
administration showed significant antinociceptive effects for each dose tested. Antinociception 
reached 35.2 ± 3.2%, 43.4 ± 8.9%, and 62.0 ±7.7 % at doses of 3, 30 and 90 µg kg-1, respectively 
(Figure 1B).  
We then assessed the efficacy of JMV2009 to alleviate the nociceptive behaviors in two 
different persistent pain paradigms, using either intraplantar formalin or intraperitoneal injection 
of acetic acid as chemical somatic and visceral noxious stimuli, respectively. Intraplantar injection 
of formalin into the right hind paw of saline-pretreated rats induced a biphasic time-dependent 
increase in pain score (Figure 2). Importantly, i.t. pretreatment with JMV2009 significantly 
reduced the stereotypical nocifensive behaviors elicited by formalin during the tonic inflammatory 
phase (21 to 60 min), without affecting the early phase (1 to 9 min) (Figure 2A). Indeed, both 
doses tested markedly abolished the spontaneous persistent pain-related behaviors, reaching 49.7% 
and 97% of inhibition at 3 and 30 µg kg-1, respectively (Figure 2B). The antinociceptive effect of 
JMV2009 was further tested using the acetic acid-induced writhing model in mice (Figure 2C). 
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We found that i.c.v. injection of JMV2009 suppressed the visceral pain behaviors in a dose-
dependent manner, reducing the number of writhes by 87% at the highest dose tested.  
 
3.3. JMV2009 attenuates neuropathy-induced mechanical hypersensitivity and 
improves the quality-of-life proxies 
We next investigated the antinociceptive action of JMV2009 in a clinically relevant model 
of chronic neuropathic pain. Neuropathic pain was induced by chronic constriction injury (CCI) of 
the sciatic nerve and the mechanical hypersensitivity was determined by applying von frey 
filaments. As shown in Figure 3, CCI rats developed tactile allodynia as soon as 3 days after 
surgery compared with preoperative values and persisted until at least 28 days. As expected, the 
paw withdrawal thresholds in response to tactile stimuli were not affected in sham-operated 
animals. Importantly, i.t. injection of JMV2009 was effective in reversing the allodynic state, even 
at the lowest dose tested (Figure 3A). Indeed, JMV2009 produced robust anti-allodynic effects, 
achieving 51.4 ± 3.4 %, 69.2 ± 3.9 % and 66.2 ± 7.6 % of pain relief at the doses of 3, 30 and 90 
µg kg-1, respectively (Figure 3B). 
To date, the development of potential analgesic agents relies mainly on the measurement of 
withdrawal responses to acute application of external heat or mechanical stimuli (e.g., von frey 
filament). However, to improve the translation of analgesics to the clinic, it may be useful to 
monitor spontaneous innate behaviors indicative of animal well-being in the preclinical drug 
screening. Accordingly, we previously demonstrated in different chronic pain models that the 
dynamic weight bearing (DWB) method could be used to measure posture-locomotor functional 
impairment and rehabilitation as well as health and quality-of-life outcomes in freely moving rats 
(50, 52). In addition to the reflexive mechanical nociceptive test, we thus used the DWB device to 
assess the effects of JMV2009 on weight load deficits and time-of-use of the injured paw. We first 
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found that i.t. delivery of JMV2009 was effective to reverse the weight bearing deficit induced by 
the chronic constriction injury of the sciatic nerve (Figure 4A). Indeed, a 30-µg kg-1 dose of 
JMV2009 significantly reduced the ipsilateral paw weight load deficits in non-restrained 
neuropathic rats, leading to a gain of 40.9 ± 6.4 % of weight recovery over the 28-day period of 
observation (Figure 4A-B). Next, we evaluated the efficacy of JMV2009 to reverse the impaired 
use of the affected limb. As shown in Figure 4C, JMV2009 improved the time spent by the animal 
on its injured paw. The drug effectiveness was also expressed as % of rehabilitation within the 
four-week period, where 100% rehabilitation corresponds to a complete recovery of the paw usage. 
This outcome parameter is considered clinically relevant and represents a good indicator of quality 
of life improvement (53). At the dose used, JMV2009 was found to improve the use of the affected 
limb to 52.8 ± 10.3% (Figure 4D). 
3.4. JMV2009 does not induce opioid or NT-driven side effects 
To achieve good analgesia, patients’ compliance to a prescribed pain treatment is of high 
importance. Among the various reasons of noncompliance, the presence of mild to severe side 
effects seriously affects medication adherence in patients with chronic pain (3). For instance, 
constipation, nausea, respiratory depression and tolerance are common clinical concerns that may 
lead to discontinuation of long-term opioid therapy. Here, we therefore assessed whether JMV2009 
could induce constipation after systemic administration. To this end, we measured the effects of 
JMV2009 and morphine on the gastrointestinal tract motility using the charcoal meal test in starved 
rats (Figure 5A). Morphine (10 mg kg-1 s.c.) was found to reduce by 45% the progression of the 
charcoal meal in the intestine, when compared to saline-treated animals. By contrast, both NT and 
JMV2009 subcutaneously injected at 10 mg kg-1 did not affect the charcoal meal intestinal transit. 
Rats treated with JMV2009 even showed an almost significant increase of the gastrointestinal tract 
motility, since the charcoal meal travelled 98.7 ± 0.8 % of the intestine (P = 0.064) compared to 
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82.2 ± 2.4 % and 87.4 ± 2.5 % when rats were treated with either NT or saline, respectively (Figure 
5A). 
We next determined whether repeated injection of JMV2009 induced the development of 
tolerance to its analgesic effect. For this purpose, rats were subjected to i.t. injections of JMV2009 
(30 µg kg-1) daily for five consecutive days, and tail-flick tests were conducted over 90 min on the 
last day to evaluate changes of JMV2009-induced antinociception. In this experimental paradigm, 
repeated JMV2009 exposure did not produce tolerance, as demonstrated by the absence of changes 
in tail-flick latency, when compared to saline pre-treated animals (Figure 5B). Finally, since NT 
administered centrally also causes hypothermia through an NTS1-dependent mechanism (51, 54), 
we measured the ability of JMV2009 to induce changes in body temperature. We found here that 
JMV2009 administered i.t. at effective analgesic doses did not induce hypothermia. In sharp 
contrast, the NTS1-selective agonist PD149163, used here as a reference compound induced a 
pronounced time-dependent drop in body temperature (Figure 5C). 
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4. Discussion 
 
G-protein coupled receptors are the target of more than 25% of the FDA-approved drugs 
(55) and represent one of the largest classes of therapeutic targets in pain medicine (56). Nowadays, 
validation of new molecular targets and development of new effective, non-addicting pain 
medications are critical, but still remain extremely slow (57, 58). In the past decades, both NTS1 
and NTS2 have generated a growing interest as potential targets for pain treatment (9-12). This 
increasing attention is probably driven in part by the fact that NT drugs act as effective opioid-free 
medications for pain management, producing significant pain relief in various animal models of 
acute and chronic pain, including neuropathic pain for which opioids have shown their limitations 
(8, 52, 59). Importantly, the combination of NT analogs to opioids has also the potential to exert 
complementary (synergistic or additive) analgesic actions, thereby minimizing the adverse effects 
related to chronic opioid use (60-62). 
In recent years, changes in the pharmaceutical industry have led to renewed interest in the 
use of peptides as therapeutics (19, 20). The current pipeline of peptide therapeutics includes over 
60 approved drugs and 150 in active clinical development, with 40% of these peptide drug 
candidates targeting GPCRs (63). The development of peptide drugs with high therapeutic potency 
remains however challenging and requires the implementation of chemical strategies and/or 
computational structural prediction to synthesize modified peptides with improved stability, 
pharmacokinetics and in vivo activity profiles. Among the chemical approaches used to optimize 
the properties of the NT(8-13) peptide, incorporation of unnatural amino acids, such as N-
methylarginine, D-ornithine, D-α-naphthylalanine, tert-leucine or L-(trimethylsilyl)alanine 
respectively at positions 8, 9, 11, 12 and 13, has been shown to be effective, increasing significantly 
NTS1 and NTS2 receptor binding affinity or selectivity as well as peptide stability and in vivo 
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biological activity (23, 26, 27, 30, 31, 64). To date, only few studies have investigated the impact 
of Pro10 substitutions on NT receptor binding and to our knowledge, none of them have evaluated 
their efficacy in vivo. The proline residue in position 10 plays a crucial role for peptide 
conformation and SAR studies reveal that substituted proline analogs that promote a reverse turn 
are more tolerated than those inducing an extended backbone conformation (22, 65, 66). Indeed, 
replacement of Pro10 by thioproline, hydroxyproline, its 4 and 6 member ring counterparts azetidine 
carboxylic acid and pipecolic acid, or Tic and Aic cyclic aromatic derivatives all induces 
conformational changes resulting in a significant loss of NT receptor binding affinity (22, 66). 
These results are consistent with the crystal structure of the NTS1-NT(8-13) complex in its 
activated-like conformation, which shows a tight oriented hydrophobic binding site for the 
pyrrolidine ring of Pro10 as well as extensive van der Waals interactions with the residue W339 in 
ECL3 (67, 68). Here, we have therefore replaced Pro10 by a silylated proline surrogate that exhibits 
very similar conformational properties that the proline residue in peptides (38, 41). The substitution 
of the γ-carbon by a dimethylsilyl group was found to slightly decrease the affinity of JMV2009 
for NTS1 while this chemical substitution seemed to be adequate for NTS2 binding. Accordingly, 
proline isostere bearing a thiazolidine unit instead of the pyrrolidine ring, as well as fluoro-
substituted proline analogs on Cγ have already been reported to be well tolerated when incorporated 
into NTS2-selective peptoids (65). This Sip-containing NT(8-13) peptide also exhibited an 
improved resistance to proteolytic degradation, probably to the endopeptidases 24.11 and 24.16 
responsible for inactivating NT by cleaving at the Pro10-Tyr11 bond (28, 69). The steric hindrance 
of the dimethyl group borne by the silicon atom could indeed induce a misrecognition of the Sip10-
Tyr11 peptide bond by these metalloendopeptidases. To further increase the plasma stability of this 
NT derivative, it would be interesting to combine the substitution of Pro10 by Sip to N-terminal 
protection through the incorporation of blocked amino group (i.e. Nα-methylarginine) at position 
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8 or reduced amide bond between position 8 and 9 as well as to replace Ile12 by a tert-leucine 
residue to avoid enzymatic cleavage at the Tyr11-Ile12 peptide bond (26, 31, 70). Importantly, this 
Sip-containing NT(8-13) analog was effective in triggering intracellular signaling responses at both 
NTS1 and NTS2, as shown by the activation of the ERK1/2 pathway (71, 72). 
We then reported the analgesic efficacy of this silylated NT(8-13) analog in different 
experimental pain models. We first found that JMV2009 was able to significantly reduce acute 
thermal pain, even at the lower dose of 3 µg kg-1. This result is consistent with previous studies 
demonstrating that both NTS1 and NTS2 agonists decrease the tail and foot withdrawal nociceptive 
responses to noxious heat stimuli (27, 61, 64, 73). In persistent pain paradigms, JMV2009 was also 
able to totally abolish the nociceptive behaviors induced by either intraplantar injection of formalin 
or visceral noxious stimulation. Interestingly, JMV2009 displays more potent analgesic effects in 
the formalin pain model than the other non-selective NT analogs, NT69L and JMV2007 previously 
described (26, 74). At equimolar dose, it is also more potent than the metabolically stable NTS2-
selective analog JMV431 in reducing the formalin-induced nocifensive behaviors (75). In the 
peripheral neuropathic pain model, JMV2009 induced relief of CCI-induced evoked 
hypersensitivity and ongoing pain. Indeed, we first observed that acute i.t. administration of 
JMV2009 was effective in reversing the development of tactile allodynia in nerve-injured rats. 
These data thus reinforce previous findings demonstrating that central or systemic delivery of either 
NTS1 or NTS2 agonists reduces the mechanical hypersensitivity in preclinical models of 
neuropathic pain (27, 52, 59, 76). Finally, and perhaps most importantly, the spinal delivery of 
JMV2009 was also able to reverse significantly the weight bearing deficits as well as to improve 
the rehabilitation outcomes. In freely moving rats, we indeed found that JMV2009 induced partial 
recovery of the weight load on the injury leg and increased the time-of-use of the affected limb. 
The monitoring of these spontaneous nociceptive-related behaviors is now considered critical for 
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evaluating the effectiveness of new drugs (77-79). Most behavioral tests currently used rely only 
on the measurement of stimuli-evoked pain behaviors, such as mechanical hyperalgesia and 
allodynia. However, neuropathic pain patients predominantly suffer from non-evoked ongoing and 
spontaneous pain, and not from stimulus-evoked hypersensitivity. This type of pain is the one 
having the most negative impact, seriously affecting the patient’s daily activities and quality of life, 
and leading to multiple comorbid conditions, such as mood and anxiety disorders, sleep 
perturbation, depression or attention deficits. Compared to the previously reported NT(8-13) 
analog, JMV431, JMV2009 produces stronger anti-allodynic effects in CCI-treated animals as well 
as substantial improvement in the management of the health and quality-of-life outcomes (52). 
Finally, when compared to typical first-and second-line medications for neuropathic pain, 
JMV2009 appeared as potent as the tricyclic antidepressant amitriptyline and more effective than 
morphine, pregabalin, gabapentin and ibuprofen in relieving spontaneous pain behaviors (52, 80-
82). 
Adherence to long-term opioid therapies represents a very clinical issue. Indeed, although 
opioids, such as morphine have been shown to be effective in relieving pain, the development of 
bothersome side effects may outweigh the benefits of opioid treatment and even lead to prompt 
discontinuation of the drug treatment (3). Constipation is particularly difficult to manage since 
patients don’t usually develop tolerance upon repeated morphine administration (83). Likewise, 
tolerance to the respiratory depressant effects of opioids develops only slowly and incompletely, 
putting patients at risk for respiratory depression with dose escalation (84). Furthermore, the long-
term use of opioids can lead to analgesic tolerance and opioid-induced hyperalgesia (85). Unlike 
morphine, we found here that both NT and JMV2009 did not cause constipation. On the contrary, 
JMV2009 seemed to induce better gastrointestinal transit compared to NT-injected rats. These 
results are consistent with previous studies demonstrating that NT stimulates colonic motility in 
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rats, cats and humans (86-88). Supporting a role for NT in propulsive colonic motility is also the 
finding that i.v. injection of NT in human subjects stimulates defecation and may improve the 
intestinal movements in colons of patients with slow transit constipation (89, 90). We further 
demonstrated that JMV2009 did not produce analgesic tolerance following chronic agonist 
treatment. Accordingly, various NT analogs, such as [D-Trp11]-NT, ABS212 and β-lactotensin do 
not induce the development of antinociceptive tolerance (27, 91, 92). Finally, we showed that 
JMV2009 was ineffective for inducing hypothermia, as opposed to the NT(8-13) agonist 
PD149163 that triggered a sustained decrease in body temperature at equimolar dose. This result 
is quite surprising since most NT agonists acting at NTS1 can produce a significant drop in body 
temperature (51, 54, 93). Nevertheless, few NT analogs acting at NTS1 were previously reported 
to be able to distinguish between hypothermia and analgesia, such as the NT(8-13) analogs, NT27 
and NT77L (94, 95). The concept of ligand biased signaling provides support to the idea that NT 
analogs acting at NTS1 may have the ability to part between analgesia and hypothermia by 
recruiting different receptor downstream signaling pathways (96). 
 
5. Conclusion 
In conclusion, we demonstrate here for the first time that the NT(8-13) peptide can 
accommodate the substitution of the proline residue to give rise to a powerful analgesic peptide. 
We further provide evidence that NT agonists do not induce the common adverse effects associated 
with the use of opioids (i.e. constipation and tolerance), thus offering a non-opioid option for the 
treatment of pain. Finally, these findings suggest that NT agonists used combined with opioid 
therapy may contribute to adequate pain relief, while reducing the severity of opioid-driven adverse 
events. 
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Figures and Figure legends 
 
 
 
Figure 1. Antinociceptive response to JMV2009 in the tail-flick test. (A) Dose- and time-
dependent antinociceptive effect of JMV2009 (3, 30, and 90 µg kg-1) on tail-flick latencies in rats. 
Baseline latencies were taken three times before acute i.t. injection of JMV2009. Latencies were 
determined every 10 min for up to 60 min and a final measure was taken at 90 min following drug 
administration. ** P < 0.01 (JMV2009, 3 µg kg-1 vs. Saline); ## P < 0.01 (JMV2009, 30 µg kg-1 vs. 
Saline); † P < 0.05, and ††† P < 0.001 (JMV2009, 90 µg kg-1 vs. Saline) in a two-way ANOVA 
followed by a Dunnett’s post hoc test. (B) Percentage of maximum possible effect (MPE) ± SEM 
determined at the time of peak anti-nociceptive response (40 min) for each dose (3, 30, and 90 µg 
kg-1). * P < 0.05 and *** P < 0.001 (JMV2009 vs. Saline) in a Kruskal-Wallis test followed by a 
Dunn’s correction for multiple comparisons. Each data point represents the mean ± SEM. n = 8 
rats per group.  
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Figure 2. Effects of central administration of JMV2009 on tonic and visceral pain. (A) 
Reduction of the nocifensive behaviors after i.t. injection of JMV2009 (3 and 30 µg kg-1) in the 
formalin-induced tonic pain model. * P < 0.05 (JMV2009, 3 µg kg-1 vs. Saline) and ### P < 0.01 
(JMV2009, 30 µg kg-1 vs. Saline) in a two-way ANOVA followed by a Dunnett’s post hoc test. 
(B) The cumulative nociceptive response, expressed as mean area under the curve (AUC) ± SEM, 
is measured during the inflammatory phase of the formalin test (21 – 60 min). *** P < 0.001 
(JMV2009 vs. Saline) in a Kruskal-Wallis test followed by a Dunn’s correction for multiple 
comparisons. Each symbol represents the mean ± SEM of determinations made in 6 rats. (C) Dose-
dependent antinociceptive effects of JMV2009 (0.4, 4, 12 and 40 µg kg-1, i.c.v.) in the acetic acid-
  39 
induced writhing model in mice. Writhes were counted over a 5-min period after i.p. injection of 
0.5% acetic acid. ** P < 0.01 and *** P < 0.001 (JMV2009 vs. Saline) in a Kruskal-Wallis test 
followed by a Dunn’s correction for multiple comparisons. The number of indicated writhes is the 
mean ± SEM from groups of 6 mice.  
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Figure 3. Effects of JMV2009 on mechanical allodynia induced by the chronic constriction 
injury (CCI) of the sciatic nerve in rats. (A) Paw withdrawal thresholds were assessed with an 
automated von Frey hair during the 4-week period after CCI surgery. Baseline (BL) withdrawal 
thresholds were determined for all CCI-and sham-operated rats prior to surgery. In neuropathic 
rats, acute i.t. injection of JMV2009 (3, 30, and 90 µg kg-1) at day 3, 7, 14, 21, and 28 post-surgery 
effectively reduces the mechanical hypersensitivity. ** P < 0.01, *** P < 0.001 (JMV2009, 3 µg 
kg-1 vs. CCI); ### P < 0.001 (JMV2009, 30 µg kg-1 vs. CCI); ††† P < 0.001 (JMV2009, 90 µg kg-1 
vs. CCI) in a two-way ANOVA followed by a Dunnett’s post hoc test. (B) Percentage of anti-
allodynia calculated over the 3-28 day period. All tested doses of JMV2009 were effective to 
attenuate the development of mechanical allodynia. *** P < 0.001 (JMV2009 vs. Saline) in a 
Kruskal-Wallis test followed by a Dunn’s correction for multiple comparisons. Vertical bars 
represent SEM (n = 6 per group).   
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Figure 4. Effects of JMV2009 on neuropathy-induced weight-bearing deficits and decrease 
in time-of-use of the injured limb. (A) Weight bearing impairment was measured using the 
dynamic weight bearing (DWB) after acute i.t. injection of JMV2009 (30 µg kg-1) at day 3, 7, 14, 
21, and 28 post-surgery. Baseline values (BL) were assessed before CCI surgery. * P < 0.05 and 
** P < 0.01 (JMV2009, 30 µg kg-1 vs. CCI) in a two-way ANOVA followed by a Dunnett’s post 
hoc test. (B) Treatment effectiveness was determined by measuring the percentage of weight 
recovery over the 3-28 day period, with 100% corresponding to full recovery in the weight borne 
on the injured limb. *** P < 0.001 in a two-tailed Mann-Whitney test. (C) Percentage of time spent 
on the injured limb was determined using the DWB device over the 28-day period following CCI 
surgery. * P < 0.05 (JMV2009, 30 µg kg-1 vs. CCI) in a two-way ANOVA followed by a Dunnett’s 
post hoc test. (D) Determination of the percentage of functional rehabilitation was examined over 
the 28-day period after acute administration of JMV2009. 100% rehabilitation corresponds to a full 
recovery in the use of the injured limb. * P < 0.05 in a two-tailed Mann-Whitney test. Each symbol 
represents the mean ± SEM of determinations made in 6 rats.   
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Figure 5. Effects of JMV2009 on opioid and neurotensin-related adverse effects. (A) 
Gastrointestinal tract motility assessed by measuring the progression of a charcoal meal in the 
intestine. Results are expressed as percentage of distance travelled by the active charcoal 30 min 
after the s.c. injection of either saline (1 mL kg-1), Morphine sulfate, neurotensin (NT), or JMV2009 
(10 mg kg-1). *** P < 0.001 (vs. Saline) in a Kruskal-Wallis test followed by a Dunn’s correction 
for multiple comparisons. Each data point represents the mean ± SEM. n = 6 rats per group. (B) 
Effect of chronic treatment with JMV2009 (30 µg kg-1 day-1, i.t. for five consecutive days) or Saline 
(25 µL day-1, i.t. for five consecutive days) on the antinociceptive action of JMV2009 (90 µg kg-
1). The analgesic effect was assessed using the tail-flick thermal test. No statistical differences were 
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found between the anti-nociceptive responses of Saline- or JMV2009-pretreated animals (two-way 
ANOVA followed by a Dunnett’s post hoc test). Each symbol represents the mean ± SEM of 
determinations made in 8 rats. (C) Hypothermia induced by acute i.t. injection of saline, JMV2009 
(3, 30, and 90 µg kg-1) and the NTS1-selective compound PD149163 (30 µg kg-1). Baseline body 
temperature (BL) assessment was performed before i.t. injection. As opposed to PD149163, 
JMV2009 did not induce changes in body temperature (Δ Body Temperature). *** P < 0.001 
(PD149163, 30 µg kg-1 vs. Saline) in a two-way ANOVA followed by a Dunnett’s post hoc test. 
Error bars represent mean ± SEM. of determinations made in 8 rats. 
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Table 
 
Table 1. Affinity of JMV2009 and NT for both NTS1 and NTS2 receptors  
 
 
Binding (IC50)a 
NT JMV2009 
hNTS1 1.2 ± 0.2 nM 15.2 ± 4.7 nM 
hNTS2 6.2 ± 0.5 nM 21.2 ± 1.9 nM 
a Values are expressed as IC50 ± SEM of at least three independent determinations 
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Supplementary materials and methods 
 
JMV2009 synthesis 
The starting Wang resin preloaded with Leucine residue was purchased from Novabiochem; Fmoc-
amino acids were obtained from ISIS Biotech. HBTU, HOBt, DIEA, TEA and piperidine were 
purchased from Aldrich. Water was obtained from Milli-Q plus system (Millipore), acetonitrile 
and trifluoroacetic acid (TFA) from Merck. Mass spectra were obtained by electron spray 
ionization (ESI-MS) on a Micromass Platform II quadrupole mass spectrometer (Micromass) fitted 
with an electrospray source coupled with a Waters HPLC.  
Analytical HPLC were performed on a RP18, 3.5 μm (4.6 × 50 mm) column, coupled to a UV-Vis 
detector. Chromatogram were obtained from a linear gradient of acetonitrile (0.1% TFA) in water 
(0.1% TFA), 0 to 100% within 15 min with a 1 mL min-1 flow. Preparative HPLC were performed 
using a RP18 5 μm (19 × 100 mm) column coupled to a UV detector (214 nm). Chromatogram 
were obtained from a linear gradient of acetonitrile (0.1% TFA or TFA free) in water (0.1% TFA 
or TFA free), with a 20 mL/min flow. Retention time (tR) are given in minutes. 
Preparative HPLC was performed on a Waters Delta-Prep 4000 chromatography equipped with a 
Waters 486 UV detector with detection at 214 nm, using a Delta-Pak C18 column (40 × 100 mm, 
15 µm, 100 Å) at a flow rate of 50 mL min-1 of a binary eluent system of A/B (A: H2O, TFA 0.1%; 
B: CH3CN, TFA 0.1%). 
The NT hexapeptide was synthesized using the solid-phase method with a Perkin-Elmer ABI433A 
automatic synthesizer on a 0.25 mmol scale with Leu-preloaded Wang resin (loading 0,84 mmol/g, 
298 mg). The coupling reagent was a 0.45 M solution of HBTU/HOBt (2ml). Four times excess of 
amino acid was used in coupling (1 mmol: Fmoc-Lys(Boc)-OH: 468 mg, Fmoc-Lys(Boc)-OH: 468 
mg, Fmoc-Ile-OH: 353 mg, Fmoc-Tyr(tBu)-OH: 459 mg, Fmoc-Sip-OH: 380 mg). The Fmoc-Sip 
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aminoacid has been synthesized according to published procedures (Martin, Vanthuyne, Miramon, 
Martinez & Cavelier, 2011; Vivet, Cavelier & Martinez, 2000). Deprotection cycles were carried 
out in piperidine:DMF (20:80, 5mL) and monitored by conductimetry. Elongation was performed 
by single 30 min couplings in DMF (15 mL) with DIEA (2 M, 1 mL) as base. Washings were 
carried out with DMF (3 × 15 mL) and DCM (1 × 15 mL). Final cleavage was carried out with a 
mixture TFA:anisole 8:2 (8 mL) for 3 hours. The resin was washed extensively with DCM. The 
filtrate was co-evaporated with hexane 5 times to remove residual TFA. The residue was taken up 
in ether (1 mL) and hexane (5 mL) was subsequently added to precipitate the peptide as a TFA salt. 
The afforded solid was dried under vacuum, and then purified on preparative HPLC, injected in an 
acetonitrile-water mixture (5/5, 10 mL). tR =22.5 min (20 – 50% B, 30 min, C18). These conditions 
afforded the expected peptide (JMV2009) in 74% yield (210 mg of TFA salt), after purification. tR 
=17.2 min (20 – 50% B, 30 min, C18). ES-MS [M+H]+ 805,7. F: 146-148°C. 
 
Western Blotting Analyses of ERK1/2 Activity 
CHO-K1 cells expressing NTS1 or 1321N1 cells expressing NTS2 were grown for 48 hours in 
their respective medium containing 10% FBS, starved in serum-free media for 16 h, and then 
stimulated for various time intervals (1-60 min) with either 1 µM of NT or JMV2009 at 37°C in 
serum-free medium. Reaction was stopped by aspiration of the medium and the addition of ice-
cold Hanks' balanced salt solution. Cells were then lysed in 50 mM HEPES, pH 7.8, containing 1% 
Triton X-100, 0.1 μM staurosporine, 1 mM sodium orthovanadate, and EDTA-free Complete 
protease inhibitor. The cell lysates were centrifuged at 8000g for 15 min at 4°C, and the 
supernatants were stored at -20°C until use. 
For each lysate, 25 μg of proteins were separated on 10% SDS-polyacrylamide gels and transferred 
on PVDF membranes as described previously (Gendron, Oligny, Payet & Gallo-Payet, 2003). 
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Membranes were blocked with TBS-T containing 3% bovine serum albumin (BSA) for 1 h at room 
temperature and incubated for 2 h at room temperature with anti-phosphorylated ERK1/2 (Cell 
Signaling, cat# 4376S, lot 18, Danvers, MA; 1:1000, in TBS-T, 1% BSA) or anti-ERK1/2 (Cell 
Signaling, cat# 4695S, lot 28; 1:1000, in TBS-T, 1% BSA) monoclonal rabbit antibodies, followed 
by three washes with TBS-T. Detection of immunoreactive proteins was accomplished using 
horseradish peroxidase-conjugated anti-rabbit IgG from goat (Cell Signaling, cat# 7074S, lot 28; 
1:5000, in TBS-T, 1% BSA) and an enhanced chemiluminescence detection system. 
 
JMV2009-induced NTS1 internalization 
CHO-K1 cells (CCL-61 from ATCC used between passage 5 and 25) were seeded in 24-well plates 
coated with poly-L-lysine (Sigma-Aldrich) at 100,000 cells per well and transfected with 375 ng 
of plasmid coding for the HA-tagged human NTS1 receptor (obtained through cdna.org) using 
Lipofectamine 2000 (Invitrogen) as previously described (Luginina et al., 2019). Forty-eight hours 
after transfection, cells were washed and stimulated with either 1 µM of NT or JMV2009 for 60 
min at 37°C in serum-free DMEM/F12. Cells were then washed with PBS and fixed with 3.7% 
(v/v) formaldehyde in tris-buffered saline (TBS; 20 mM tris-HCl (pH 7.5) and 150 mM NaCl) for 
5 min at RT. Cells were washed three times with TBS and incubated for 1 hour in TBS 
supplemented with 3% fat-free milk (w/v) to block nonspecific binding sites. A mouse monoclonal 
anti-HA antibody coupled to horseradish peroxidase (Roche) was added at 1:1000 dilution in TBS 
with 3% fat-free dry milk for 3 hours at RT. Following incubation, cells were washed twice with 
TBS before the addition of 250 l of 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich). Plates were 
incubated at RT for 15 min, and the reaction was stopped by the addition of 250 l of 2N HCl. 200 
l of the colorimetric reaction was transferred into a 96-well plate, and the absorbance was read at 
450 nm on a Tecan Genios Pro plate reader. Cells transfected with the empty pcDNA3.1(+) were 
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used to determine the background. Data were plotted and normalized by using GraphPad Prism 
7.0a.  
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Supplementary Scheme S1. Chemical structure of the JMV2009. 
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Supplementary Figures 
 
 
Supplementary Figure S1. Synthetic procedure for the hexapeptide JMV2009.  
The hexapeptide was synthesized by the solide-phase method using the Wang resin preloaded with 
Leucine residue. The 9-fluorenylmethyloxycarbonyl (Fmoc) protection was used as temporary 
protection of the N-terminal amino groups, and N-tert-Butyloxycarbonyl (Boc) and tert-Butyl 
(tBu) were used for the side-chain protections. Couplings of protected amino acids were carried 
out with a solution of HBTU/HOBt reagents. The use of the Wang resin allowed peptide release 
from the resin and the deprotection of side chains of the desired protected peptide with TFA in the 
presence of anisole as scavenger. The resulting peptide JMV 2009 was purified by preparative 
reverse-phase HPLC on a C18 column and its structure was confirmed by ESI mass spectrometry.  
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Supplementary Figure S2: Plasmatic stability of JMV2009.  
NT and JMV2009 were incubated at various time points in rat plasma. After protein precipitation, 
the supernatant was analyzed on HPLC/UV as a ratio of the area under the curve (AUC) of the 
intact peptide over the area under the curve (AUC) of an internal standard (i.e. Fmoc-Glycine). 
JMV2009 exhibits greater resistance to proteolytic degradation than the native NT peptide, 
showing 6.24 ± 2.9 and 1.49 ± 0.4 min plasma half-life, respectively. 
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Supplementary Figure S3. Effect of JMV2009 stimulation on ERK1/2 activation and receptor 
internalization.  
(A-D) Cells stably expressing either NTS1 or NTS2 were serum starved for 24h before stimulation 
with either 1 µM NT or JMV2009. Western blots represent immunoreactivity against 
phosphorylated p42/p44 (pERK1/2) or total p42/p44 (Total ERK1/2) proteins. CHO-K1 cells 
stably expressing NTS1 stimulated with JMV2009 (A) or NT (B) 1321N1 cells stably expressing 
NTS2 stimulated with JMV2009 (C) or NT (D). (E) HA-hNTS1 transfected CHO-K1 cells were 
stimulated with 1 µM of NT or JMV2009 for 1 hour. Non-stimulated cells represent the 0% of 
internalization whereas the mock-transfected cells correspond to the maximum achievable 
internalization (100% of internalization). 
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